How do granulomatosis with polyangiitis and anti‑glomerular basement membrane disease cause interstitial lung disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How GPA and Goodpasture Syndrome Cause Interstitial Lung Disease

GPA (granulomatosis with polyangiitis) causes interstitial lung disease through necrotizing granulomatous inflammation and neutrophilic capillaritis driven by ANCA-mediated neutrophil activation, while Goodpasture syndrome (anti-GBM disease) causes pulmonary injury through autoantibodies against type IV collagen in alveolar basement membranes, leading to alveolar hemorrhage rather than classic ILD patterns 1, 2.

Distinct Pathogenic Mechanisms

GPA-Associated ILD Pathogenesis

GPA causes lung injury through multiple overlapping mechanisms:

  • ANCA-mediated neutrophil activation: PR3-ANCA (proteinase 3) antibodies, present in 80-90% of GPA cases, activate primed neutrophils, leading to degranulation and release of toxic mediators 3
  • Neutrophil extracellular trap (NET) formation: Activated neutrophils release NETs containing chromatin and antimicrobial proteins, perpetuating inflammation and tissue damage 1
  • Necrotizing granulomatous inflammation: Formation of granulomas with multinucleated giant cells and microabscesses, characteristic of GPA 4
  • Neutrophilic capillaritis: Small vessel inflammation causing direct alveolar and interstitial injury 4

The ILD pattern in GPA differs from typical idiopathic interstitial pneumonias - surgical lung biopsies reveal neutrophilic capillaritis, microabscesses with giant cells, and coexisting usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP) patterns 4.

Anti-GBM Disease (Goodpasture Syndrome) Pathogenesis

Anti-GBM disease operates through a fundamentally different mechanism:

  • Autoantibodies against type IV collagen: Specifically target the α3 chain of type IV collagen in alveolar and glomerular basement membranes 5
  • Linear IgG deposition: Antibodies bind directly to basement membranes, causing complement activation and inflammatory cell recruitment 6
  • Alveolar hemorrhage predominates: Rather than causing fibrotic ILD, anti-GBM disease typically manifests as diffuse alveolar hemorrhage 7
  • Pulmonary-renal syndrome: Simultaneous lung and kidney injury is the hallmark presentation 7

Critical distinction: Anti-GBM disease does not typically cause interstitial lung disease in the fibrotic sense - it causes alveolar hemorrhage, which is a different pattern of lung injury 2.

Clinical Patterns and Timing

GPA-ILD Characteristics

ILD in GPA can present in three temporal patterns 8:

  1. ILD preceding vasculitis diagnosis (22.1% of cases) - particularly in MPO-ANCA positive patients (85.7%)
  2. ILD at time of AAV diagnosis (66.3% of cases)
  3. ILD developing during disease course

Radiologic patterns vary by ANCA type 8:

  • NSIP pattern: Most common in PR3-ANCA (c-ANCA) positive patients (60.9%)
  • UIP pattern: More common in MPO-ANCA (p-ANCA) positive patients (47.7%)
  • Subpleural reticular opacities with traction bronchiectasis are characteristic 4

Anti-GBM Disease Presentation

Anti-GBM disease presents acutely with 5:

  • Diffuse alveolar hemorrhage causing hemoptysis and hypoxemia
  • Rapidly progressive glomerulonephritis
  • Symptoms developing over days to weeks, not the chronic progressive course of ILD

Diagnostic Approach

For Suspected GPA-ILD

When ILD is detected in a patient with suspected vasculitis 4, 8:

  1. Serologic testing: PR3-ANCA and MPO-ANCA - both can be associated with ILD, but MPO-ANCA correlates more strongly with UIP pattern
  2. High-resolution CT chest: Look for NSIP or UIP patterns, not just nodules or cavities
  3. Consider surgical lung biopsy when diagnosis is uncertain - reveals characteristic neutrophilic capillaritis and granulomatous inflammation that distinguishes GPA-ILD from idiopathic ILD 4
  4. Screen for systemic vasculitis features: Sinonasal involvement, glomerulonephritis, peripheral neuropathy 9, 7

For Suspected Anti-GBM Disease

Within 24 hours of presentation with pulmonary-renal syndrome 5:

  1. Anti-GBM antibody testing - diagnostic hallmark
  2. ANCA testing - 10-40% have concurrent ANCA positivity ("double-positive disease") 7, 10
  3. Thoracic imaging - diffuse ground-glass opacities from hemorrhage, not reticular patterns
  4. Kidney biopsy - shows linear IgG deposits along glomerular basement membrane 6
  5. Exclude infection before initiating immunosuppression

Common Diagnostic Pitfalls

GPA frequently mimics infection or malignancy 11, 12:

  • Cavitary lung masses can appear hypermetabolic on PET scan, suggesting cancer
  • Coexisting bacterial infections (Pseudomonas, Haemophilus) are common and can obscure the diagnosis
  • Partial response to empiric antibiotics or corticosteroids may delay recognition of underlying vasculitis
  • Non-diagnostic biopsies showing only inflammation without characteristic granulomas

The key distinguishing feature: Persistent or progressive disease despite appropriate antimicrobial therapy, combined with ANCA positivity and systemic features, should trigger consideration of GPA 11, 12.

Treatment Implications

GPA-ILD Treatment

Follow standard AAV remission induction protocols 9, 13:

  • Rituximab preferred over cyclophosphamide for remission induction
  • Reduced-dose glucocorticoid regimen (starting with pulse methylprednisolone 3 grams total, then rapid taper)
  • Maintenance therapy with rituximab for 24-48 months

ILD-specific considerations: The presence of ILD does not fundamentally change AAV treatment, but requires pulmonary monitoring during therapy 14.

Anti-GBM Disease Treatment

Requires urgent, aggressive therapy 5:

  • Plasmapheresis (plasma exchange) - essential component, unlike in isolated AAV
  • Glucocorticoids plus cyclophosphamide (rituximab as alternative)
  • Treatment must begin within 24 hours to preserve renal function
  • Maintenance therapy not required unless concurrent ANCA positivity present

Double-positive disease (anti-GBM + ANCA): Treat as anti-GBM disease with plasma exchange, but continue maintenance immunosuppression as for AAV 9, 13, 10.

References

Research

Pathogenesis of lung vasculitis.

Seminars in respiratory and critical care medicine, 2011

Research

[Vasculitides and anti-GBM disease].

Innere Medizin (Heidelberg, Germany), 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.